Compare Citius Pharmaceuticals Inc (CTXR) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Gap Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Gap Inc trades at $20.53 (market cap $7.25B). The key difference: Gap Inc is far larger — about 495.2× Citius Pharmaceuticals Inc's market cap, and Gap Inc pays a 3.48% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GAP | |
|---|---|---|
Market Cap | $14.64M | $7.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $29.13 |
52-Week Low | $0.53 | $18.35 |
Enterprise Value | $10.86M | $10.33B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Gap Inc. (GAP) trades at $19.80, up 1.75% today, with a bearish technical signal despite neutral oscillators. The stock shows strong fundamentals with a P/E of 7.86 and net income margin of 6.25%, supported by a 10-quarter positive comp trend. Recent news highlights a digital transformation with AI-led marketing and ongoing legal investigations.
The outlook is mixed; valuation metrics suggest upside to the $27 consensus target, but near-term risks include legal probes and Athleta's turnaround pace. Earnings growth and margin expansion remain key catalysts, though investor sentiment is cautious amid bearish technicals and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
